Healthcare / BiotechnologyLSE
$1670.00
-10.00 (-0.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $7.8M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$87M
P/E
11.7x
↓EV/EBITDA
858.5x
↑ROE
65.7%
↑Gross Margin
90.9%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.8%
FCF CAGR
-2.4%
FCF margin
53.5%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.1M · net income $7.6M · FCF $7.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.1M | $13.1M | $13.6M | $12.8M | $11.7M |
| Net Income | $7.6M | $7.6M | $8.1M | $8.4M | $7.7M |
| EBITDA | $10.2M | $10.2M | $10.7M | $10.2M | $9.4M |
| EPS | 1.43 | 1.43 | 152.86 | 1.58 | 1.46 |
| Gross Margin | 90.9% | 90.9% | 93.2% | 93.5% | 93.9% |
| Operating Margin | 76.8% | 76.8% | 78.1% | 78.6% | 78.3% |
| Net Margin | 57.8% | 57.8% | 59.5% | 65.3% | 65.5% |
| Balance Sheet | |||||
| Current Ratio | 6.12 | 6.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.0M | $7.0M | $8.3M | $7.8M | $7.5M |
| Returns | |||||
| ROE | 65.7% | 65.7% | 67.5% | 69.4% | 64.9% |
| Valuation | |||||
| P/E | 11.70 | 11.70 | 28.95 | 2432.40 | 2330.36 |
| EV/EBITDA | 858.53 | 858.53 | 2181.84 | 1996.11 | 1897.47 |
| P/B | 756.01 | 756.01 | 1952.81 | 1688.08 | 1512.84 |
| Growth & Yield | |||||
| Revenue Growth | -3.6% | -3.6% | 6.2% | 9.4% | — |
| EPS Growth | -99.1% | -99.1% | 9557.6% | 8.5% | — |
| Dividend Yield | 9.0% | 9.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
369.4%
EPS terminal req.
$148.18
Spread vs growth
-468.4%
5Y implied EPS CAGR
162.7%
EPS terminal req.
$179.30
Spread vs growth
-261.8%
10Y implied EPS CAGR
70.0%
EPS terminal req.
$288.77
Spread vs growth
-169.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.1%
Start / end P/E
18.6x → 1151.5x
EPS bridge
152.86 → 1.43
Residual
-6019.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.